Chordate Medical AB
Gunilla Lundmark is an accomplished executive and board member with extensive experience in various sectors, particularly in the commercialization of research. Currently serving as CEO of Uppsala universitet Invest AB and a board member for multiple companies, including SampleFacts, CombiGene, Lipidor AB, UIC - Uppsala Innovation Centre, and Chordate Medical Holding AB, Gunilla Lundmark has a strong focus on innovation in pharmaceuticals and healthcare. Gunilla Lundmark has held leadership roles such as Chairman of the Board at Strike Pharma AB and has contributed to the board at Innovationsstiftelsen vid Handelsbanken Uppsala City. Gunilla Lundmark holds an Executive MBA and a BSc from Uppsala University, further enhancing a solid foundation in business management and development.
This person is not in the org chart
This person is not in any teams
Chordate Medical AB
Chordate Medical is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Ozilia™ Migraine. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm.